Background for Promotions.png

Webinar Series

Imaging Biomarkers in NASH Drug Development

Non-alcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide with a global prevalence of 25% and the incidence and economic burden is likely to increase further with the worsening global epidemic of obesity. A sub-group of patients with NAFLD progress to Non-alcoholic Steatohepatitis (NASH), a severe sub-type that is associated with increased morbidity and mortality. Reliable diagnosis of NASH can only be made by histopathological examination of a liver biopsy specimen and its use in clinical trials to evaluate therapy is associated with significant challenges.

In this webinar, we discuss the current status of imaging biomarkers in NASH including molecular imaging, pathology and putative genetic biomarkers, and the challenges associated with the integration of imaging biomarkers in clinical trials.

Saleem Azeem, M.D., Ph.D.
Matthew Silva, Ph.D.

Register Now to Watch it On-Demand:

About The Speakers

Matthew Silva, Ph.D.
CEO, Invicro

Dr. Silva is CEO of Invicro and leads the strategic vision and mission to support the the drug discovery and development community.

Dr. Silva holds a PhD in Biomedical Engineering from Worcester Polytechnic Institute and brings 17 years of diverse imaging experience from pharmaceutical and contract research organizations. Prior to Invicro, he was Senior Director of Translational Biology at Vertex Pharmaceuticals, where he ran the imaging and histopathology groups. Previously, he led imaging groups at Amgen, Millennium and Takeda Pharmaceuticals, focusing on the broad use of imaging biomarkers to support drug discovery and development.

Saleem Azeem, M.D., Ph.D.
Head of Oncology and Respiratory Medicine, Invicro

Dr. Saleem Azeem is the Head of Oncology Applications at Invicro, London where he heads the oncology and non-neuroscience clinical applications.  In his role, Dr. Azeem is responsible for developing and implementing translational clinical imaging studies in oncology and other therapeutic areas such as respiratory medicine, hepatology, inflammatory joint, bowel and systemic diseases to support clinical drug development.  He also provides clinical and scientific expertise to support Invicro projects globally across therapeutic areas.  He has an honorary appointment as a Clinical Senior Lecturer at the Imperial College London and is the author of a peer-reviewed publications.

Saleem is a clinical oncologist by training and is a Fellow of the Royal College of Radiologists (Clinical Oncology), UK and obtained his PhD from the University of London researching the utility of positron emission tomography (PET) in anti-cancer drug development.  He practiced as an honorary consultant in clinical oncology at the Christie Hospital NHS Trust, Manchester UK before he joined GlaxoSmithKline Clinical Imaging Centre, London to develop the translational oncology imaging portfolio and was head of oncology applications at Imanova, London prior to his current position,